AU2012267489B2 - System and method of cytomic vascular health profiling - Google Patents
System and method of cytomic vascular health profiling Download PDFInfo
- Publication number
- AU2012267489B2 AU2012267489B2 AU2012267489A AU2012267489A AU2012267489B2 AU 2012267489 B2 AU2012267489 B2 AU 2012267489B2 AU 2012267489 A AU2012267489 A AU 2012267489A AU 2012267489 A AU2012267489 A AU 2012267489A AU 2012267489 B2 AU2012267489 B2 AU 2012267489B2
- Authority
- AU
- Australia
- Prior art keywords
- subject
- microparticles
- mps
- cytometric
- progenitor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 93
- 230000006438 vascular health Effects 0.000 title claims abstract description 33
- 239000011859 microparticle Substances 0.000 claims abstract description 302
- 210000000130 stem cell Anatomy 0.000 claims abstract description 130
- 239000012472 biological sample Substances 0.000 claims abstract description 48
- 210000004027 cell Anatomy 0.000 claims description 95
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 69
- 238000000684 flow cytometry Methods 0.000 claims description 52
- 230000006492 vascular dysfunction Effects 0.000 claims description 30
- 238000003556 assay Methods 0.000 claims description 29
- 230000003511 endothelial effect Effects 0.000 claims description 28
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 26
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 26
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims description 19
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims description 19
- 102100040120 Prominin-1 Human genes 0.000 claims description 18
- 210000001616 monocyte Anatomy 0.000 claims description 14
- 230000002250 progressing effect Effects 0.000 claims description 12
- 102100029761 Cadherin-5 Human genes 0.000 claims description 8
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 230000001023 pro-angiogenic effect Effects 0.000 claims description 5
- -1 CD31 Proteins 0.000 claims description 4
- 102100037241 Endoglin Human genes 0.000 claims description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 description 138
- 238000004458 analytical method Methods 0.000 description 67
- 239000011324 bead Substances 0.000 description 65
- 239000000090 biomarker Substances 0.000 description 50
- 239000000523 sample Substances 0.000 description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 45
- 201000010099 disease Diseases 0.000 description 39
- 210000004369 blood Anatomy 0.000 description 28
- 239000008280 blood Substances 0.000 description 28
- 238000009826 distribution Methods 0.000 description 27
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 22
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 22
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 21
- 238000001514 detection method Methods 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 239000003550 marker Substances 0.000 description 19
- 238000005259 measurement Methods 0.000 description 19
- 239000002245 particle Substances 0.000 description 19
- 108090000672 Annexin A5 Proteins 0.000 description 18
- 102000004121 Annexin A5 Human genes 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 18
- 230000002526 effect on cardiovascular system Effects 0.000 description 17
- 230000001105 regulatory effect Effects 0.000 description 17
- 201000001320 Atherosclerosis Diseases 0.000 description 15
- 102000007330 LDL Lipoproteins Human genes 0.000 description 15
- 238000004163 cytometry Methods 0.000 description 15
- 108010028554 LDL Cholesterol Proteins 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 230000004087 circulation Effects 0.000 description 12
- 230000007774 longterm Effects 0.000 description 12
- 206010020772 Hypertension Diseases 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 102000000412 Annexin Human genes 0.000 description 8
- 108050008874 Annexin Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 108010074051 C-Reactive Protein Proteins 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 7
- 102000002262 Thromboplastin Human genes 0.000 description 7
- 108010000499 Thromboplastin Proteins 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 230000036996 cardiovascular health Effects 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 102000003951 Erythropoietin Human genes 0.000 description 6
- 108090000394 Erythropoietin Proteins 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- 230000003143 atherosclerotic effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 208000029078 coronary artery disease Diseases 0.000 description 6
- 238000007405 data analysis Methods 0.000 description 6
- 229940105423 erythropoietin Drugs 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 102100032752 C-reactive protein Human genes 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000005779 cell damage Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- 206010048554 Endothelial dysfunction Diseases 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 4
- 238000000585 Mann–Whitney U test Methods 0.000 description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 4
- 101710112672 Probable tape measure protein Proteins 0.000 description 4
- 101710204224 Tape measure protein Proteins 0.000 description 4
- 208000024248 Vascular System injury Diseases 0.000 description 4
- 208000012339 Vascular injury Diseases 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 230000007211 cardiovascular event Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000008694 endothelial dysfunction Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 3
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 3
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 3
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 3
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 3
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000000702 anti-platelet effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000005315 distribution function Methods 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000013160 medical therapy Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 3
- 230000002947 procoagulating effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012502 risk assessment Methods 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 229960001790 sodium citrate Drugs 0.000 description 3
- 235000011083 sodium citrates Nutrition 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012706 support-vector machine Methods 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 101710149632 Pectinesterase A Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 108091006374 cAMP receptor proteins Proteins 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 230000034303 cell budding Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 238000000205 computational method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000005574 cross-species transmission Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000003066 decision tree Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 108091005995 glycated hemoglobin Proteins 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000012316 non-parametric ANOVA Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000003805 procoagulant Substances 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000007637 random forest analysis Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000006444 vascular growth Effects 0.000 description 2
- 230000006439 vascular pathology Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000011546 CRP measurement Methods 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000013600 Diabetic vascular disease Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 1
- 101000797623 Homo sapiens Protein AMBP Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 238000012351 Integrated analysis Methods 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 101150044441 PECAM1 gene Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 238000001358 Pearson's chi-squared test Methods 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 102100032859 Protein AMBP Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 101710190759 Serum amyloid A protein Proteins 0.000 description 1
- 102100032277 Serum amyloid A-1 protein Human genes 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 229940127174 UCHT1 Drugs 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007635 classification algorithm Methods 0.000 description 1
- 238000013145 classification model Methods 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 108010027836 endotoxin receptor Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 101150094737 pdm2 gene Proteins 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003133 propidium iodide exclusion Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000007483 tonsillectomy Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Dispersion Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161495955P | 2011-06-10 | 2011-06-10 | |
| US61/495,955 | 2011-06-10 | ||
| US201261650353P | 2012-05-22 | 2012-05-22 | |
| US61/650,353 | 2012-05-22 | ||
| PCT/US2012/041792 WO2012170974A1 (en) | 2011-06-10 | 2012-06-10 | System and method of cytomic vascular health profiling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012267489A1 AU2012267489A1 (en) | 2014-01-09 |
| AU2012267489B2 true AU2012267489B2 (en) | 2017-03-16 |
Family
ID=47296510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012267489A Ceased AU2012267489B2 (en) | 2011-06-10 | 2012-06-10 | System and method of cytomic vascular health profiling |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140357505A1 (enExample) |
| EP (1) | EP2717681A4 (enExample) |
| JP (1) | JP6059211B2 (enExample) |
| CN (1) | CN104039134A (enExample) |
| AU (1) | AU2012267489B2 (enExample) |
| CA (1) | CA2838436A1 (enExample) |
| WO (1) | WO2012170974A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015134791A2 (en) * | 2014-03-07 | 2015-09-11 | University Of Washington - Center For Commercialization | Non-invasive biomarker of antibody-mediated allograft rejection |
| JP2015123503A (ja) * | 2014-08-21 | 2015-07-06 | 千住金属工業株式会社 | 真空はんだ処理装置及びその制御方法 |
| JP2018505392A (ja) * | 2014-12-10 | 2018-02-22 | ネオゲノミクス ラボラトリーズ， インコーポレイテッド | 自動化されたフローサイトメトリ分析方法及びシステム |
| FR3030039B1 (fr) * | 2014-12-12 | 2018-03-16 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Caracterisation et reproduction d'un jugement d'expert pour une classification binaire |
| CA3012985A1 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| ES2829235T3 (es) * | 2015-05-07 | 2021-05-31 | Oncoimmune Inc | Uso de CD24 para disminuir los niveles de colesterol en lipoproteínas de baja densidad |
| WO2017162722A1 (en) * | 2016-03-22 | 2017-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Free functional annexin levels in plasma as a biomarker of cardiovascular risk |
| JPWO2020138351A1 (enExample) * | 2018-12-28 | 2020-07-02 | ||
| CN116359488A (zh) * | 2021-12-27 | 2023-06-30 | 北京积水潭医院 | 检测血液样本中不同类型微颗粒含量的方法 |
| CN114674729B (zh) * | 2022-03-02 | 2023-11-21 | 迈克医疗电子有限公司 | 脉冲识别方法、装置、存储介质、设备及血液细胞分析仪 |
| CN120778688A (zh) * | 2025-07-09 | 2025-10-14 | 广州市微米生物科技有限公司 | 一种流式检测试剂在肿瘤疾病的出血风险等级分类产品中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090233999A1 (en) * | 1999-09-06 | 2009-09-17 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
| US7708977B2 (en) * | 2002-11-15 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Method for diagnosis and treatment of vascular disease |
| WO2005069003A1 (en) * | 2003-06-27 | 2005-07-28 | Oklahoma Medical Research Foundation | Methods for predicting susceptibility to cardiovascular disease |
| US20050272098A1 (en) * | 2004-04-23 | 2005-12-08 | Tramontano Anthony F | Quantitation of endothelial microparticles |
| US20060078553A1 (en) * | 2004-10-07 | 2006-04-13 | Paul Glidden | Diverse multi-unit complexes including a tRNA synthetase fragment |
| US20100203058A1 (en) * | 2009-02-11 | 2010-08-12 | Indiana University Research And Technology Corporation | Diagnostics and therapeutics based on circulating progenitor cells |
| WO2011000874A1 (en) * | 2009-07-01 | 2011-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting cardiovascular mortality risk |
-
2012
- 2012-06-10 EP EP12796754.5A patent/EP2717681A4/en not_active Withdrawn
- 2012-06-10 WO PCT/US2012/041792 patent/WO2012170974A1/en not_active Ceased
- 2012-06-10 CA CA2838436A patent/CA2838436A1/en not_active Abandoned
- 2012-06-10 CN CN201280039113.1A patent/CN104039134A/zh active Pending
- 2012-06-10 US US14/123,920 patent/US20140357505A1/en not_active Abandoned
- 2012-06-10 JP JP2014514915A patent/JP6059211B2/ja not_active Expired - Fee Related
- 2012-06-10 AU AU2012267489A patent/AU2012267489B2/en not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| Curtis, et al., 'Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic population', Cytometry Part B: Clinical Cytometry, 2010, Vol. 78, pages 329-337. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6059211B2 (ja) | 2017-01-11 |
| CA2838436A1 (en) | 2012-12-13 |
| WO2012170974A1 (en) | 2012-12-13 |
| JP2014517313A (ja) | 2014-07-17 |
| EP2717681A1 (en) | 2014-04-16 |
| US20140357505A1 (en) | 2014-12-04 |
| EP2717681A4 (en) | 2015-01-07 |
| AU2012267489A1 (en) | 2014-01-09 |
| CN104039134A (zh) | 2014-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012267489B2 (en) | System and method of cytomic vascular health profiling | |
| Nielsen et al. | A flow cytometric method for characterization of circulating cell-derived microparticles in plasma | |
| Urrechaga et al. | Role of leucocytes cell population data in the early detection of sepsis | |
| Kurtzman et al. | Personalized cytomic assessment of vascular health: evaluation of the vascular health profile in diabetes mellitus | |
| JP2015514227A (ja) | 結核バイオマーカーおよびその使用 | |
| JP7605502B2 (ja) | Ｄｍａｒｄに対する患者の応答を予測する方法 | |
| US20250334589A1 (en) | Methods for the detection and quantification of circulating endothelial cells | |
| Rose et al. | Flow cytometric quantification of peripheral blood cell β-adrenergic receptor density and urinary endothelial cell-derived microparticles in pulmonary arterial hypertension | |
| Li et al. | Single urinary extracellular vesicle proteomics identifies complement receptor CD35 as a biomarker for sepsis-associated acute kidney injury | |
| Yang et al. | Diagnosis of paroxysmal nocturnal hemoglobinuria in peripheral blood and bone marrow with six-color flow cytometry | |
| Oris et al. | Measurement of S100B protein: evaluation of a new prototype on a bioMérieux Vidas® 3 analyzer | |
| Siwaponanan et al. | Enumeration and phenotyping of circulating microvesicles by flow cytometry and nanoparticle tracking analysis: Plasma versus serum | |
| EP2534491B1 (en) | Compositons and methods for predicting cardiovascular events | |
| WO2022101554A1 (en) | Method for determining whether a subject is at risk of developing a chronic respiratory disease | |
| De Simone et al. | Circulating endothelial cell levels in psoriatic patients and their modification after an anti‐TNF‐alpha (Etanercept) treatment | |
| FI130377B (en) | Procedure for determining whether a subject is at risk of developing an anxiety disorder | |
| Maréchal et al. | Neutrophil dynamics in acute coronary syndrome | |
| CA3208461A1 (en) | Method for determining whether a subject is at risk of dying from breast cancer or prostate cancer | |
| US20100120080A1 (en) | Cancer diagnosis using ki-67 | |
| CN121114427A (zh) | 一种评价系统性红斑狼疮疾病严重性及临床转归的标志物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ MOHLER, EMILE R.; MOORE, JONNI S.; ZHANG, LIFENG; ROGERS, WADE AND BANTLY, ANDREW D. - 29 - |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |